Next Generation Antibody-Drug Conjugate Developed Using Catalent’s SMARTag® ADC Technology Triphase Accelerator Corporation, a company dedicated to acquiring and developing novel therapeutics for the treatment of cancer, and Catalent, the leading global provider of...
Soliton, Inc., (NASDAQ: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”),...
Modern medicines have positively contributed to public health and changed the ways human diseases are prevented and treated. Yet, most drugs are not without side effects. Adverse drug reactions (ADRs) rank among the leading causes of morbidity and mortality worldwide....
Stand Up To Cancer (SU2C) is helping scientists make progress in one of the most important areas of cancer research today: expanding the use of autologous CAR T-cell immunotherapy beyond leukemia and other blood cancers to solid tumors such as osteosarcoma and...
– 19% objective response rate and 36% clinical benefit rate, with 13-month median duration of response in melanoma patients whose disease progressed on or after anti-PD-1 therapy – – Gene expression analyses provide mechanistic insight for enhanced...
The investigational therapeutic umbralisib, which targets the molecule PI3K-delta, was well tolerated and highly active in patients with relapsed/refractory marginal zone lymphoma, according to early results from the UNITY-NHL phase II clinical trial, which were...
Email
Text